Buyback announced
As filed · Record Date
What happened
Factof the company, each having face value of INR 5.00/- (Indian Rupees Five Only), representing 2.23% of the total equity. price of INR 1,000 (Indian Rupees One Thousand Only) per equity share (“Buyback Price”), payable in cash. (“SEBI Buy-Back Regulations”) provided that 15% (fifteen percent) of the number of Equity Shares which the Company.
Why it matters
CapitSignal interpretationA buyback returns cash by retiring shares, so the benefit to a holder depends on the price paid, how many of their shares are accepted, and what the stub is worth afterwards.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Capex
WithdrawnWe are on track for the commercialization of Plant-6 in H1 FY27, which will further strengthen our manufacturing capacity and enable us to support future growth opportunities.
Our Injectables and Plant-2 Extension facilities continue to drive scalable growth, highlighting the effectiveness of our strategic investments.
Change
FactImplication
CapitSignal interpretationWatch next
Fact- Record date and acceptance ratio
- Promoter participation
- Cash left on the balance sheet afterwards
- We are on track for the commercialization of Plant-6 in H1 FY27, which will further strengthen our manufacturi (management committed by H1 FY27)
Evidence
- Windlas Biotech Limited has informed the Exchange that Record date for the purpose of BB is 24-Apr-2026.(opens the original filing in a new tab)
- Earlier statement · Q1 FY27
- Latest statement · Q1 FY27
How CapitSignal classified this
- Reasoning:
- BUYBACK base 70; +2 corroborating keywords; +5 quantified amount; +3 quantified percentage; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 90%